Cannabis and cardiotoxicity

Forensic Science, Medicine, and Pathology

Volumn 2, Issue 1, 2006, Pages 13-18

  Karch, Steven B ^a  

^a Department of Cardiac Pathology/Toxicology ^*  (United States)

Author keywords

Cannabinoids; Coronary artery disease; Sudden cardiac death; THC

Indexed keywords

EID: 33646877264     PISSN: 1547769X     EISSN: None     Source Type: Journal    
DOI: 10.1385/FSMP:2:1:13     Document Type: Review

References (49)

1. UN Office for Drug Control and Crime Prevention. World Drug Report for 2005. Geneva: United Nations, Office on Drugs and Crime, 2005.
2. Studies, O.o.A. National Survey on Drug Use & Health. Bethesda, MD: Substance Abuse and Mental Health Services Administration, 2005.
3. American Heart Association. Heart disease and stroke statistics - 2005 update. Dallas, TX: author, 2005.
4. Charles R, Holt S, Kirkham N. Myocardial infarction and marijuana. Clin Toxicol 1979;14(4):433-438.
5. Collins JS, Higginson JD, Boyle DM, Webb SW. Myocardial infarction during marijuana smoking in a young female. Eur Heart J 1985;6(7):637-638.
6. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001;103(23):2805-2809.
7. Lindsay AC, Foale RA, Warren, Henry JA. Cannabis as a precipitant of cardiovascular emergencies. Int J Cardiol 2005;104(2):230-232.
8. Caldicott DG, Holmes J, Roberts-Thomson KC, Mahar L. Keep off the grass: marijuana use and acute cardiovascular events. Eur J Emerg Med 2005;12(5):236-244.
9. Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol 2002;42(11 Suppl):58S-63S.
10. Servoss SJ, Januzzi JL, Muller JE. Triggers of acute coronary syndromes. Prog Cardiovasc Dis 2002:44(5):369-380.
11. Virmani R, Burke AP, Farb A. Sudden cardiac death. Cardiovasc Pathol 2001;10(5):211-218.
12. Bachs L, Morland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001;124(2-3):200-203.
13. Fisher BA, Ghuran A, Vadamalai V, Antonios TF. Cardiovascular complications induced by cannabis smoking: a case report and review of the literature. Emerg Med J 2005;22(9):679-680.
14. Nattel S. Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol? Nat Clin Pract Cardiovasc Med 2005;2(7):332-333.
15. Wagner JA, Abesser M, Karcher J, Laser M, Kunos G. Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. J Cardiovasc Pharmacol 2005;46(3):348-355.
16. Thakur GA, Nikas SP, Makriyannis A. CB1 cannabinoid receptor ligands. Mini Rev Med Chem 2005:5(7):631-640.
17. Huffman JW. CB2 receptor ligands. Mini Rev Med Chem 2005;5(7):641-649.
18. Ueda N, Okamoto Y, Tsuboi K. Endocannabinoid-related enzymes as drug targets with special reference to N-acylphosphatidylethanolamine-hydrolyzing phospholipase D. Curr Med Chem 2005;12(12):1413-1422.
19. Bisogno T, Ligresti A, Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav 2005;81(2):224-238.
20. ElSohly M, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;2005 (e-published ahead of schedule).
21. Mechoulam R, Hanus L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids 2000;108 (1-2):1-13.
22. Batkai S, Pacher P, Osei-Hyiaman D, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004;110(14):1996-2002.
23. Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 1975;18(3):287-297.
24. O'Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD. Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliterator-activated receptor gamma. Biochem Biophys Res Commun 2005;337(3):824-831.
25. Newlin D, Pretorius MB, Wong CJ, Dax EM. Acute marijuana smoking reduces vagal tone. NIDA Res Monogr 1991;(105):565-565.
26. Anon. Youth Tobacco Surveillance - United States 2000, in Surveillance Summaries. Atlanta, GA: Center of Disease Control, 2001, pp. 1-84.
27. Bradford-Hill A. The environment and disease: Association or causation? President's address. Proceedings of the Royal Society of Medicine. 1965;9:295-300.
28. Chen Z, Boreham J. Smoking and cardiovascular disease. Semin Vasc Med 2002;2(3):243-252.
29. Sidney S. Cardiovascular consequences of marijuana use. J Clin Pharmacol 2002;42(11 Suppl):64S-70S.
30. Aronow WS, Cassidy J. Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med 1974;291(2); 65-67.
31. Mouzak A, Agathos P, Kerezoudi E, Mantas A, Vourdeli-Yiannakoura E. Transient ischemic attack in heavy cannabis smokers - how 'safe' is it? Eur Neurol 2000;44(1):42-44.
32. Cooles P, Michaud R. Stroke after heavy cannabis smoking. Postgrad Med J 1987;63(740):511.
33. Zachariah SB. Stroke after heavy marijuana smoking. Stroke 1991;22(3):406-409.
34. White D, et al. Stroke associated with marijuana abuse. Pediatr Neurosurg 2000;32:92-94.
35. Gupta BD, Jani CB, Shah PH. Fatal 'Bhang' poisoning. Med Sci Law 2001;41(4):349-352.
36. Finsterer J, Christian P, Wolfgang K. Occipital stroke shortly after cannabis consumption. Clin Neurol Neurosurg 2004;106(4):305-308.
37. Geller T, Loftis L, Brink D. Cerebellar infarction in adolescent males associated with acute marijuana abuse. Pediatrics 2004;106:305-308.
38. Coros C, Sorce A. PDR 60th edition. Montvale, NJ: Thompson-PDR.
39. Garrett ER, Hunt CA. Physiochemical properties, solubility, and protein binding of delta9-tetrahydrocannabinol. J Pharm Sci 1974;63(7):1056-1064.
40. Agurell S, Leander K. Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec 1971;8(4):391-402.
41. Wahlqvist M, Nilsson IM, Sandberg F, Agurell S. Binding of delta-1-tetrahydrocannabinol to human plasma proteins. Biochem Pharmacol 1970;19(9):2579-2584.
42. Lemberger L, Tamarkin NR, Axelrod J, Kopin IJ. Delta-9- tetrahydrocannabinol: metabolism and disposition in long-term marihuana smokers. Science 1971;173(991):72-74.
43. Kreuz DS, Axelrod J. Delta-9-tetrahydrocannabinol: localization in body fat. Science 1973;179(71):391-393.
44. Levisky JA, Bowerman DL, Jenkins WW, Johnson DG, Karch SB. Drugs in postmortem adipose tissues: evidence of antemortem deposition. Forensic Sci Int 2001;121(3):157-160.
45. Johnson JR, Jennison TA, Peat MA, Foltz RL. Stability of delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in blood and plasma. J Anal Toxicol 1984;8(5):202-204.
46. McCurdy HH, Callahan LS, Williams RD. Studies on the stability and detection of cocaine, benzoylecgonine, and 11-nor-delta-9-tetrahydrocannabinol- 9-carboxylic acid in whole blood using Abuscreen radioimmunoassay. J Forensic Sci 1989;34(4):858-870.
47. Christophersen AS. Tetrahydrocannabinol stability in whole blood: plastic versus glass containers. J Anal Toxicol 1986;10(4):129-131.
48. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148(3):293-300.
49. Huestis MA, Gorelick DA, Heishman SJ, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001;58(4):322-328.